![](/img/cover-not-exists.png)
22 24-months on treatment: Open-label phase I/II long-term study of enzyme replacement therapy (ERT) with Gene-Activated® human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease
Ari Zimran, G. Altarescu, C. Fratazzi, R. Mensah, D. ElsteinVolume:
92
Year:
2007
Language:
english
DOI:
10.1016/j.ymgme.2007.08.027
File:
PDF, 46 KB
english, 2007